Meta Pixel

News and Announcements

Actinogen Medical CEO Interview

  • Published September 23, 2016 11:18AM UTC
  • Publisher Wholesale Investor
  • Categories Executive Interviews

Actinogen Medical Ltd (ASX: ACW) is an Australian, publicly-listed early clinical-stage biotechnology company focused on the treatment of cognitive impairment and Alzheimer’s disease.

Actinogen is developing Xanamem™ as a novel treatment approach to Alzheimer’s disease and other age-related neurodegenerative diseases. Xanamem™ displays high potency and selectivity for inhibiting the activity of a key enzyme in the brain, which converts cortisone to cortisol. Cortisol is also known as the stress hormone, and elevated levels of cortisol has previously been linked to cognitive impairment. The pivotal human proof of concept study, also known as XanADu, commenced in 2Q2016.

Please listen to Dr. Bill Ketelbey, Founder and CEO & Managing Director of Actinogen Medical below.

Company Updates
The A$20.4 Million Inertia Trap: How Kepa Software Is Unlocking Value in Enterprise Capital Allocation

A government agency renewed the same maintenance decision nine years running, because auditing the original choice was deemed too expensive. When the portfolio was finally tested, A$20.4 million of low value spend was identified in a single year. Kepa Software’s capital governance platform was built to expose and eliminate precisely these boardroom blind spots. For […]

Company Updates
The prefab company that deliberately leaves part of the house unbuilt

BuiltQuik prefabricates the floor and roof structure and stops there. Co-founder Ryan Mullaney argues the omission is the product. Prefabricated housing usually means a factory. A large central facility, identical modules, limited room to move on design, and a logistics problem getting the finished box to site. BuiltQuik builds the opposite, and the design decision […]

Join over 45,000+ sophisticated investors

Join Now